Improving Access to HCV Care in Key Populations

Review data on improving hepatitis C care in vulnerable populations by increasing access to care and streamlining testing and diagnosis.
Stacey Trooskin, MD, PhD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 2.60 MB
Released: November 2, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AbbVie

Related Content

Clinical Care Options (CCO): A patient perspective on receiving a diagnosis of HCV and cirrhosis during the COVID-19 pandemic

person default Anonymous Patient Released: January 26, 2022

Review key slides on the interplay of COVID-19 and viral hepatitis and review expert strategies for managing chronic liver disease in the COVID-19 era

Released: January 10, 2022

Clinical Care Options (CCO) and Dr. Robert Gish: Interplay of COVID-19 and viral hepatitis, expert strategies for chronic liver disease in the COVID era

Robert G. Gish, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Limitations of the APASL guidelines and potential role of using HBcrAg for treatment candidacy and HCC screening, from Clinical Care Options (CCO)

Yasuhito Tanaka, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 3, 2022 Expired: January 2, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings